Kit CEO plans to learn drug pricing strategy from Gilead

Source: Ding Xiangyuan's 2015-01-19 kit executives said this week that they plan to have a dialogue with insurance companies this year on some experimental cancer drugs that, if effective and approved by regulators, could cost hundreds of thousands of dollars Although these potential drugs have not yet started large-scale clinical trials, due to previous conflicts between medical insurance companies and Gilead science company on reducing the cost of hepatitis C drugs, biotechnology companies and pharmaceutical companies need to consider how to deal with the adverse factors brought about by this event Asked in an interview at the JPMorgan medical conference about how to secure financing for an immunotherapy cancer drug that could cost hundreds of thousands of dollars, kit's chief executive, bellegrun, said, "we'll learn from our mistakes." This treatment method is still in the early stage of development, but it has been paid close attention to because the cure rate is much higher than the current cancer treatment scheme The insurance company's efforts to lower drug prices took an important step in December, when Alberta launched Gilead's competitive products, while express scripts, the largest profit manager in China, reduced Gilead's drug coverage in its large pharmacy program involving 25 million people Gilead's drug prices outside the US are lower, and according to Wall Street analysts, it is also starting to lower prices in the US When the company was asked in time for the meeting, analysts reported that the company had cut its price by 30%, which Geely did not comment on Kit will soon begin a large number of clinical trials of immunotherapy drugs for cancer, in which cells come from the human body, are sent to the laboratory for treatment, and then introduced into the individual's blood stream The test is expected to be completed in the second half of 2016 Kite's financial model sets a benchmark price of $150000 per treatment, but the actual price will depend more on survival and the efficacy of the drug, says butita, chief financial officer Analysts estimate that each treatment will cost as much as $300000 The company's new head of marketing will begin talks with insurers next month about the benefits available for trials and treatments "We will start this year," says butita Kit recently signed a partnership agreement with Amgen, one of several companies developing this type of immunotherapy for cancer, including Novartis, Bluebird biology and Juno medical